These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32741580)

  • 1. Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.
    Pereira AAL; Fernandes GDS; Braga GTP; Marchetti KR; Mascarenhas CDC; Gumz B; Crosara M; Dib L; Girardi D; Barrichello A; Seidler H
    Clin Colorectal Cancer; 2020 Dec; 19(4):e264-e271. PubMed ID: 32741580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
    Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
    Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
    Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
    Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between clinicopathological characteristics and RAS mutation in colorectal cancer.
    Rimbert J; Tachon G; Junca A; Villalva C; Karayan-Tapon L; Tougeron D
    Mod Pathol; 2018 Mar; 31(3):517-526. PubMed ID: 29052598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Bajjou T; Sekhsokh Y; Benmokhtar S; Jafari M; Baba W; Oukabli M; El Annaz H; Abi R; Tagajdid MR; El Kochri S; Lahlou IA; Ameziane El Hassani R; Ennibi K
    Cancer Control; 2024; 31():10732748241262179. PubMed ID: 38875469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
    J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using tumor habitat-derived radiomic analysis during pretreatment
    Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
    Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
    Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
    Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component.
    Wei Q; Wang X; Gao J; Li J; Li J; Qi C; Li Y; Li Z; Shen L
    PLoS One; 2016; 11(6):e0156659. PubMed ID: 27300552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
    Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
    Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.